Revolution Medicines, Inc. (RVMD)

Market Cap	7.64B
Revenue (ttm)	742,000
Net Income (ttm)	-567.06M
Shares Out	184.80M
EPS (ttm)	-3.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,030,991
Open	42.80
Previous Close	42.26
Day's Range	41.27 - 42.94
52-Week Range	28.95 - 62.40
Beta	1.45
Analysts	Strong Buy
Price Target	65.15 (+57.6%)
Earnings Date	Feb 26, 2025

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 13, 2020
• Employees: 378
• Stock Exchange: NASDAQ
• Ticker Symbol: RVMD
• Website: https://www.revmed.com

Financial Performance

In 2023, Revolution Medicines's revenue was $11.58 million, a decrease of -67.27% compared to the previous year's $35.38 million. Losses were -$436.37 million, 75.5% more than in 2022.

Analyst Forecast

According to 13 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price forecast is $65.15, which is an increase of 57.60% from the latest price.

Price Target

$65.15

(57.60% upside)

Analyst Consensus: Strong Buy